GLAXOSMITHKLINE UK LIMITED

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

http://uk.gsk.com/

Address

980 Great West Road Brentford, Middlesex

Brentford
TW8 9GS
United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with GLAXOSMITHKLINE UK LIMITED
Sign up free

Contracts awarded to GLAXOSMITHKLINE UK LIMITED

The contracts that GLAXOSMITHKLINE UK LIMITED have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 1 month ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 5 months ago
Award

Published 1 month ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 1 month ago

DTaP/IPV/Hib+HepB vaccine (2025)

A contract for the supply of DTaP/IPV/Hib+HepB vaccine, to be used as part of the national childhood immunisation programme. Deliveries will be required over a period of 2 years, with an option to extend for up to an additional 24 months. Value - The value has been withheld so as not to prejudice the legitimate commercial interest of the supplier.

Bids close: 9 months ago
Award

Published 1 month ago

DTaP/IPV/Hib+HepB vaccine (2025)

Contract for the supply of DTaP/IPV/Hib+HepB vaccine

£1
Award

Published 4 months ago

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)

Invitation to offer for NHS National Generic Pharmaceuticals - Wave 14c Offer reference number: CM/PHG/22/5672 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN):01/06/2024 to 31/05/2027 (36 Months) Hospital Only Products: DLS & DNE: 01/06/2024 to 31/05/2026(24 months) Hospital Only Products(Housekeeping): DLN & DNW: 01/06/2024 to 31/01/2025(8 months) DCE & DSW: 01/06/2024 to 30/09/2025(16 months)

£424,035,364 Bids close: 9 months ago
Award

Published 4 months ago

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024 Offer reference number: CM/PHR/22/5682 CM/PHR/22/5682/01 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 1. Period of framework: 1 May 2024 to 30 April 2028. CM/PHR/22/5682/02 - NHS Framework Agreement for Branded Medicines - National Tender - Lot 2. Period of framework: 1 May 2024 to 30 April 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Bids close: 9 months ago

GLAXOSMITHKLINE UK LIMITED

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to GLAXOSMITHKLINE UK LIMITED

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England

DTaP/IPV/Hib+HepB vaccine (2025)

DTaP/IPV/Hib+HepB vaccine (2025)

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win